Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Nu Holdings
NU
5
Liberty Latin America-A
LILA
HK Stock MarketDetailed Quotes
06160 BEIGENE
- 152.200
- +0.700+0.46%
Not Open Apr 24 16:08 CST
213.22BMarket Cap-42.60P/E (TTM)
154.500High148.400Low9.64MVolume149.700Open151.500Pre Close1.46BTurnover0.75%Turnover RatioLossP/E (Static)1.40BShares178.00052wk High8.24P/B195.70BFloat Cap85.00052wk Low--Dividend TTM1.29BShs Float278.600Historical High--Dividend LFY4.03%Amplitude61.050Historical Low151.140Avg Price100Lot Size--Div YieldTTM--Div Yield LFY
About BEIGENE Company
The company's mission is to become a global leader in the discovery, development and commercialization of innovative molecular-targeted immuno-oncology drugs to treat cancer. The company focuses on R&D, production and commercialization of innovative drugs. The main products are anti-tumor drugs, etc.
Company Profile
Symbol06160
Company NameBEIGENE
ISINKYG1146Y1017
Listing DateAug 8, 2018
Issue Price108.00
Shares Offered65.60M share(s)
FoundedJun 28, 2018
Registered AddressCayman Islands
Chairmanleiqiang ou
Secretaryqingling zhou
Audit InstitutionErnst & Young, Ernst & Young LLP, Ernst & Young AG, Ernst & Young AG
Company CategoryOverseas registration of Mainland Individuals control
Registered OfficeMourant Governance Services (Cayman) Limited 94 Solaris Avenue Camana Bay Grand Cayman KY1-1108, Cayman Islands
Head Office and Principal Place of BusinessRoom 1901, 19th floor, Lee Garden Phase 1, 33 Hysan Avenue, Causeway Bay, Hong Kong
Fiscal Year Ends12-31
Employees11000
MarketHong Kong motherboard
Phone010-58958058
Fax010-85148699
Emailir@beigene.com
Websitehttp://www.beigene.com
BusinessBeiGene is a global, commercial-stage biotechnology company focused on the research, development, production and commercialization of innovative medicines.
Company Executives
- Name
- Position
- Salary
- leiqiang ou
- Presidencies, CEOs, Executive Director, Authorized Representative
- --
- xiaodong wang
- Non-executive Directors
- --
- Olivier Brandicourt
- Independent Non-Executive Director, Audit Committee Members
- --
- Margaret Han Dugan
- Independent Non-Executive Director, Remuneration Committee Chairman, Member of the Advisory Committee on Commercial and Medical Affairs
- --
- Michael Goller
- Independent Non-Executive Director, Nomination and Corporate Governance Committee Members
- --
- Anthony C. Hooper
- Independent Non-Executive Director, Chairman of the Nomination Committee, Audit Committee Members
- --
- Ranjeev Krishana
- Independent Non-Executive Director, Remuneration Committee Members
- --
- Shalini Sharp
- Independent Non-Executive Director, Chairman of the Audit Committee, Nomination Committee Members
- --
- Alessandro Riva
- Independent Non-Executive Director, Nomination Committee Members
- --
- Corazon (Corsee) D. Sanders
- Independent Non-Executive Director, Audit Committee Members
- --
- qingqing yi
- Independent Non-Executive Director, Remuneration Committee Members
- --
- xiaobin wu
- President, General Manager, Chief Operating Officer
- --
- Aaron Rosenberg
- Chief Financial Officer
- --
- lai wang
- Global Head of R&D
- --
- Chan Lee
- Senior Vice President, General Counsel
- --
- qingling zhou
- Authorized Representative, Company Secretary
- --
Market Insights
Warren Buffett Portfolio Warren Buffett Portfolio
Buffett's holdings are the latest portfolio from Berkshire Hathaway. Regarded as a top investor, his trades often signal the market and influence the industry. Buffett's holdings are the latest portfolio from Berkshire Hathaway. Regarded as a top investor, his trades often signal the market and influence the industry.
Unlock Now
Discussing
2025 Buffett shareholders' meeting: What's the new buzz in value investing?
🎙️Discussion 1. In the face of market changes, do you prefer to stick with growth stocks or switch to value stocks? 2. Based on the current
Moomoo News Global
Apr 9 20:29
Learning From Buffett: Investing Wisely Amid Market Volatility Triggered by Trump's Tariffs